

Zhongxia Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/635803/publications.pdf>

Version: 2024-02-01

26
papers

730
citations

516215

16
h-index

552369

26
g-index

26
all docs

26
docs citations

26
times ranked

763
citing authors

#	ARTICLE	IF	CITATIONS
1	The development of an effective synthetic route of rilpivirine. BMC Chemistry, 2021, 15, 22.	1.6	5
2	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. Bioorganic and Medicinal Chemistry, 2021, 42, 116239.	1.4	3
3	Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP. Bioorganic Chemistry, 2021, 116, 105353.	2.0	5
4	Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. Communications Chemistry, 2019, 2, .	2.0	24
5	Molecular design opportunities presented by solvent-exposed regions of target proteins. Medicinal Research Reviews, 2019, 39, 2194-2238.	5.0	28
6	Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus. Organic and Biomolecular Chemistry, 2019, 17, 3202-3217.	1.5	39
7	Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors. Drug Discovery Today, 2019, 24, 629-635.	3.2	35
8	Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors by exploring the structure-activity relationship of solvent-exposed regions I. Chemical Biology and Drug Design, 2019, 93, 430-437.	1.5	13
9	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1348-1351.	1.0	13
10	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the NNRTI Adjacent Binding Site. ACS Medicinal Chemistry Letters, 2018, 9, 334-338.	1.3	32
11	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery. ACS Medicinal Chemistry Letters, 2018, 9, 370-375.	1.3	28
12	Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017). Expert Opinion on Therapeutic Patents, 2018, 28, 299-316.	2.4	36
13	Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored hydrophobic channel. Organic and Biomolecular Chemistry, 2018, 16, 1014-1028.	1.5	26
14	Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics. Drug Discovery Today, 2018, 23, 503-518.	3.2	42
15	Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2-d]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors. Chemical Biology and Drug Design, 2018, 92, 2009-2021.	1.5	16
16	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization. European Journal of Medicinal Chemistry, 2017, 130, 209-222.	2.6	30
17	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants. Journal of Medicinal Chemistry, 2017, 60, 4424-4443.	2.9	79
18	Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP. ACS Medicinal Chemistry Letters, 2017, 8, 1188-1193.	1.3	30

#	ARTICLE	IF	CITATIONS
19	1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5779-5789.	1.4	16
20	Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2). <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 9-15.	2.4	9
21	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. <i>European Journal of Medicinal Chemistry</i> , 2017, 126, 190-201.	2.6	17
22	First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via a "privileged scaffold"™ refining approach. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5182-5186.	1.0	33
23	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4424-4433.	1.4	12
24	Design, Synthesis, and Evaluation of Thiophene[3,2- <i>d</i>]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7991-8007.	2.9	107
25	Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5- <i>b</i>]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach. <i>Chemical Biology and Drug Design</i> , 2016, 88, 241-253.	1.5	12
26	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1863-1872.	1.4	40